Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
136 hedge funds and large institutions have $1.02B invested in Acceleron Pharma in 2016 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 17 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 35
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
33% more capital invested
Capital invested by funds: $766M → $1.02B (+$256M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% more funds holding
Funds holding: 128 → 136 (+8)
80% less call options, than puts
Call options by funds: $870K | Put options by funds: $4.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$20.9M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$16.1M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$8.09M |
| 4 |
Goldman Sachs
New York
|
+$6.49M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$29.7M |
| 2 |
DM
Deerfield Management
New York
|
-$9.33M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.5M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$5.33M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$4.07M |
XLRN Hedge Fund Activity: Q2 2016 in Review
136 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2016, worth a combined $1.02B — up 33% from $766M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XLRN positions and 17 closed out — a net gain of 9 holders — while 54 added to existing stakes and 35 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $20.9M. The largest seller was Sectoral Asset Management, cutting an estimated $29.7M.
- 136 institutional investors held Acceleron Pharma (XLRN) as of Q2 2016, up from 128 in Q1 2016.
- Funds reported $1.02B of Acceleron Pharma stock for Q2 2016, up 33% quarter-over-quarter.
- 26 funds opened new Acceleron Pharma positions in Q2 2016 and 17 closed out, a net change of +9 holders.
- The largest Acceleron Pharma buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $20.9M added.
- The largest Acceleron Pharma seller in Q2 2016 was Sectoral Asset Management, an estimated $29.7M sold.
Based on aggregated 13F filings for Q2 2016.